Agenus Inc
AGEN
查看详细走势图
3.440USD
-0.070-1.99%
收盘 12/19, 16:00（美东）报价延迟15分钟
112.88M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.99%
5天
-9.23%
1月
-18.48%
6月
-28.03%
今年开始到现在
+25.55%
1年
+21.55%
查看详细走势图
TradingKey Agenus Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Agenus Inc当前公司基本面数据相对谨慎，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名131/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价12.33。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Agenus Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
12.333
目标均价
+206.04%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Agenus Inc亮点
亮点风险
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
估值低估
公司最新PE估值-2.19，处于3年历史低位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值2.57M
Agenus Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Agenus Inc简介
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
公司代码AGEN
公司Agenus Inc
CEOArmen (Garo H)
网址https://agenusbio.com/
常见问题
Agenus Inc(AGEN)的当前股价是多少？
Agenus Inc(AGEN)的当前股价是 3.440。
Agenus Inc的股票代码是什么？
Agenus Inc的股票代码是AGEN。
Agenus Inc股票的52周最高点是多少？
Agenus Inc股票的52周最高点是7.340。
Agenus Inc股票的52周最低点是多少？
Agenus Inc股票的52周最低点是1.380。
Agenus Inc的市值是多少？
Agenus Inc的市值是112.88M。
Agenus Inc的净利润是多少？
Agenus Inc的净利润为-227.43M。
现在Agenus Inc(AGEN)的股票是买入、持有还是卖出？
根据分析师评级，Agenus Inc(AGEN)的总体评级为买入，目标价格为12.333。
Agenus Inc(AGEN)股票的每股收益（EPS TTM）是多少
Agenus Inc(AGEN)股票的每股收益（EPS TTM）是-1.572。
相关品种
